Johnson & Johnson is acquiring Firefly Bio for $1 billion in cash to add a degrader antibody platform aimed at hard-to-treat ...
June 8 (Reuters) - Johnson & Johnson said on Monday it will acquire biotech Firefly Bio for $1 billion in cash, as it looks ...
Under the German "individueller Heilversuch" regulatory framework, the patient received an 11-peptide personalized immunotherapy designed without tumor biopsy, using the patient's HLA genotype and ...
ADCs have become a core pillar of cancer treatment as increasingly sophisticated design is translating into stronger efficacy ...
BETHESDA, VA, UNITED STATES, June 12, 2026 /EINPresswire.com/ -- Integrating Bioinformatics, Machine Learning, and ...
Targeted therapies and immunotherapies offer new treatment options for more types of cancer, but these drugs are less helpful when tumors produce multiple copies of a gene. This gene amplification ...
Massive Bio, a global leader in AI-driven precision oncology and clinical trial matching operating across 17+ countries, and ...
Johnson & Johnson will acquire Firefly Bio for $1 billion, adding cancer-targeting technology to expand its oncology pipeline ...
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview of the expected readout from Gritstone Bio’s neoantigen cancer vaccine study. Before the end of the ...
Gritstone Bio said Monday afternoon that its personalized cancer vaccine didn’t induce more responses than standard of care in a trial for colorectal cancer, raising questions about the future of both ...
Cancer arises when the normal controls on cell growth, differentiation and death are subverted. Under physiological conditions, cells proliferate only in response to external stimuli, replicate their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results